Phathom Pharmaceuticals Inc (PHAT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Phathom Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 9.00 $ — 6% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 68.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 68.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -125.9%
- Expected return > 10% 28.3%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 61.6% passed
- Share count grows by less than 3% a year 23.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 121.6% passed
- Gross margin at 40% or higher and without meaningful erosion 87.1% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 186 m failed
- Return on capital at 15% or higher, or up versus two years ago -125.9% failed
- Insiders hold at least 10% or are net buyers 4.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 143.3% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.00 | -0.09 – 0.04 | 317 | 99.8% | 3 |
| 12/31/2027 | 1.20 | 0.92 – 1.51 | 494 | 36,118.0% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.05 | – | 30 | 4,249.60 | -251.00 | -64 | -64 |
| 2025: Q1 | -1.31 | – | 29 | 1,391.60 | -330.70 | -85 | -85 |
| 2025: Q2 | -1.05 | – | 40 | 439.40 | -191.90 | -63 | -63 |
| 2025: Q3 | -0.41 | – | 50 | 202.70 | -60.50 | -14 | -14 |
| 2025: Q4 | -0.29 | – | 58 | 94.10 | -36.70 | -5 | -5 |
| 2026: Q1 | -0.37 | – | 58 | 104.40 | -52.10 | -16 | -16 |
| 2026: Q2 | -0.21 | 80.00 | 74 | 88.10 | -23.70 | -2 | -2 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 0 | -1 | -1 | -0.15 | -1 | -1 | 1 |
| 2019 | 0 | -106 | -210 | -8.48 | -37 | 228 | 257 |
| 2020 | 0 | -126 | -129 | -3.88 | -70 | 194 | 295 |
| 2021 | 0 | -135 | -144 | -3.89 | -148 | 72 | 189 |
| 2022 | 0 | -172 | -198 | -5.05 | -147 | -75 | 165 |
| 2023 | 1 | -167 | -202 | -3.93 | -138 | -73 | 414 |
| 2024 | 55 | -277 | -334 | -5.29 | -267 | -254 | 378 |
| 2025 | 175 | -160 | -221 | -3.03 | -167 | -438 | 259 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Phathom Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
| Employees | 371 |
|---|---|
| Headquarters | Florham Park, NJ |
| Address | 100 Campus Drive, 07932 Florham Park, United States |
| Phone | 877 742 8466 |
| Website | phathompharma.com |
| IPO Date | 25. Oct 2019 |
| ISIN | US71722W1071 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Steven L. Basta M.B.A. | CEO, President & Director | 1966 |
| David A. Socks | Co-Founder | 1975 |
| Azmi Nabulsi M.D., M.P.H. | Co-Founder | 1960 |
| Sanjeev Narula | Chief Financial & Business Officer | 1961 |
| Anne Marie Cook Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1962 |
| Jonathan Bentley | Senior VP and Head of Sales, Operations & Training | – |
| Robert Breedlove | VP of Finance & Principal Accounting Officer | – |
| Eric Sciorilli | Director of Business Development & Investor Relations | – |
| Bill Aprea J.D. | Senior VP, Chief Compliance Officer & Deputy Chief Legal Officer | – |
| Nancy R. Phelan | Senior Vice President of Marketing & Analytics | 1969 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 14. Jul 2026 | Breedlove Robert Charles | Principal Accounting Officer | Other | 1,555 | 11.04 | 17,159 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.